Sangamo Therapeutics Inc., a genomic medicine company, has announced that its investigational gene therapy, isaralgagene civaparvovec, has received significant regulatory designations from various health authorities. The U.S. Food and Drug Administration (FDA) has granted the therapy Orphan Drug, Fast Track, and RMAT designations, while the European Medicines Agency has provided Orphan Medicinal Product designation and PRIME eligibility. Additionally, the U.K. Medicines and Healthcare products Regulatory Agency has included it in the Innovative Licensing and Access Pathway. These designations are expected to expedite the development and potential approval of the therapy, which aims to treat Fabry disease. Sangamo is preparing a Biologics License Application $(BLA.AU)$ submission for 2026, following positive results from the Phase 1/2 STAAR study.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。